mazindol has been researched along with Parkinson Disease in 20 studies
Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Distinguishing Alzheimer's disease from DLB is clinically relevant in terms of prognosis and appropriate treatment." | 1.30 | Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. ( Ballard, C; Burn, D; Court, JA; Jaros, E; Johnson, M; Lloyd, S; Marshall, EF; McKeith, IG; Perry, EK; Perry, RH; Piggott, MA; Thomas, N, 1999) |
| "Both Parkinson's disease and progressive supranuclear palsy populations were characterized by a marked loss of [3H]mazindol binding sites in the neostriatum (about 75%) and in the nucleus accumbens (about 65%)." | 1.28 | Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol. ( Alvarez, FJ; Chinaglia, G; Palacios, JM; Probst, A, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.00) | 18.7374 |
| 1990's | 11 (55.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kunikowska, G | 1 |
| Jenner, P | 2 |
| Wiley, RG | 1 |
| Harrison, MB | 1 |
| Levey, AI | 1 |
| Lappi, DA | 1 |
| Porritt, M | 1 |
| Stanic, D | 1 |
| Finkelstein, D | 1 |
| Batchelor, P | 1 |
| Lockhart, S | 1 |
| Hughes, A | 1 |
| Kalnins, R | 1 |
| Howells, D | 1 |
| Turle-Lorenzo, N | 1 |
| Maurin, B | 1 |
| Puma, C | 1 |
| Chezaubernard, C | 1 |
| Morain, P | 1 |
| Baunez, C | 1 |
| Nieoullon, A | 1 |
| Amalric, M | 1 |
| Delwaide, PJ | 1 |
| Martinelli, P | 1 |
| Schoenen, J | 1 |
| Gnanalingham, KK | 1 |
| Milkowski, NA | 1 |
| Smith, LA | 1 |
| Hunter, AJ | 1 |
| Marsden, CD | 1 |
| Przedborski, S | 1 |
| Levivier, M | 2 |
| Jiang, H | 1 |
| Ferreira, M | 1 |
| Jackson-Lewis, V | 1 |
| Donaldson, D | 2 |
| Togasaki, DM | 1 |
| Murray, AM | 1 |
| Weihmueller, FB | 1 |
| Marshall, JF | 2 |
| Hurtig, HI | 1 |
| Gottleib, GL | 1 |
| Joyce, JN | 2 |
| Hao, R | 1 |
| Norgren, RB | 1 |
| Lau, YS | 1 |
| Pfeiffer, RF | 1 |
| Howells, DW | 1 |
| Liberatore, GT | 1 |
| Wong, JY | 1 |
| Donnan, GA | 1 |
| Piggott, MA | 1 |
| Marshall, EF | 1 |
| Thomas, N | 1 |
| Lloyd, S | 1 |
| Court, JA | 1 |
| Jaros, E | 1 |
| Burn, D | 1 |
| Johnson, M | 1 |
| Perry, RH | 1 |
| McKeith, IG | 1 |
| Ballard, C | 1 |
| Perry, EK | 1 |
| Tanji, H | 1 |
| Araki, T | 2 |
| Fujihara, K | 2 |
| Nagasawa, H | 1 |
| Itoyama, Y | 2 |
| Augood, SJ | 1 |
| Hollingsworth, ZR | 1 |
| Standaert, DG | 1 |
| Emson, PC | 1 |
| Penney, JB | 1 |
| Matsubara, M | 1 |
| Kato, H | 1 |
| Imai, Y | 1 |
| Chinaglia, G | 1 |
| Alvarez, FJ | 1 |
| Probst, A | 1 |
| Palacios, JM | 1 |
| Weihmuller, FB | 1 |
| Ulas, J | 1 |
| Nguyen, L | 1 |
| Cotman, CW | 1 |
| Niznik, HB | 1 |
| Fogel, EF | 1 |
| Fassos, FF | 1 |
| Seeman, P | 1 |
| D'Amato, RJ | 1 |
| Zweig, RM | 1 |
| Whitehouse, PJ | 1 |
| Wenk, GL | 1 |
| Singer, HS | 1 |
| Mayeux, R | 1 |
| Price, DL | 1 |
| Snyder, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Disclosure of Dopamine Transporter Imaging Studies in PD Clinical Trials[NCT00354003] | 800 participants (Anticipated) | Observational | 2006-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for mazindol and Parkinson Disease
| Article | Year |
|---|---|
Mazindol in the treatment of Parkinson's disease.
Topics: Clinical Trials as Topic; Double-Blind Method; Female; Humans; Indoles; Male; Mazindol; Parkinson Di | 1983 |
19 other studies available for mazindol and Parkinson Disease
| Article | Year |
|---|---|
Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 an | 2003 |
Destruction of midbrain dopaminergic neurons by using immunotoxin to dopamine transporter.
Topics: Animals; Antibodies, Monoclonal; Binding, Competitive; Cell Death; Denervation; Disease Models, Anim | 2003 |
Dopaminergic innervation of the human striatum in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dop | 2005 |
The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Attention Deficit Disorder with Hyperactivity; Cognition; Corpus Stri | 2006 |
Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Autoradiography; Callit | 1995 |
Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine.
Topics: Animals; Apomorphine; Autoradiography; Behavior, Animal; Disease Models, Animal; Dose-Response Relat | 1995 |
Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Autoradiography; Benzamides; Bindi | 1995 |
Cerebrospinal fluid of Parkinson's disease patients inhibits the growth and function of dopaminergic neurons in culture.
Topics: Aged; Animals; Biological Factors; Biological Transport; Cell Division; Cells, Cultured; Dopamine; E | 1995 |
Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases.
Topics: Aged; Aged, 80 and over; Autoradiography; Benzazepines; Dopamine; Female; Humans; Male; Mazindol; Mi | 1993 |
Dopaminergic responses to striatal damage.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain Tissue Transplantation; Corpus Striatum; Dihyd | 1996 |
Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Autoradiography; Corpus Striatum; Dementia; Dopamine; Fe | 1999 |
Alteration of neurotensin receptors in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Corpus Striatum; Dopamine; D | 1999 |
Localization of dopaminergic markers in the human subthalamic nucleus.
Topics: Benzamides; Benzazepines; Biomarkers; Dopamine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Hu | 2000 |
Metabolic changes after injection of quinolinic acid or 6-hydroxydopamine in the rat striatum: a time-course study using cytochrome oxidase and glycogene phosphorylase a histochemistry.
Topics: Animals; Autoradiography; Benzazepines; Biomarkers; Corpus Striatum; Disease Models, Animal; Dopamin | 2000 |
Gamma-aminobutyric acidA and benzodiazepine receptor alterations in the rat brain after unilateral 6-hydroxydopamine lesions of the medial forebrain bundle.
Topics: Animals; Dopamine; Dopamine Uptake Inhibitors; Down-Regulation; Flunitrazepam; GABA Agonists; GABA M | 2002 |
Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.
Topics: Aged; Aged, 80 and over; Autoradiography; Basal Ganglia; Carrier Proteins; Corpus Striatum; Dopamine | 1992 |
Elevated NMDA receptors in parkinsonian striatum.
Topics: Aged; Autoradiography; Carrier Proteins; Corpus Striatum; Dopamine Plasma Membrane Transport Protein | 1992 |
The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus.
Topics: Affinity Labels; Aged; Azides; Binding Sites; Binding, Competitive; Carrier Proteins; Caudate Nucleu | 1991 |
Aminergic systems in Alzheimer's disease and Parkinson's disease.
Topics: Alzheimer Disease; Biogenic Amines; Brain; Choline O-Acetyltransferase; Citalopram; Humans; Imiprami | 1987 |